# US 2022/0033479 A1 · Anti-hepatitis c virus antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033479 A1
- Document ID: US20220033479A1
- Status: Published application
- Kind: A1
- Application number: 17/309,796
- Filed: 2019-12-19
- Published: 2022-02-03
- Earliest claimed: 2018-12-19
- Assignees: Bar-Ilan University
- Applicants: Bar Ilan University
- Inventors: Meital GAL-TANAMY; Gur YAARI; Shiri ELMEDVI; Sivan ELIYAHU; Oz SHARABI
- Web page: https://patentgrep.com/patent/US20220033479A1

## CPC

- C07K 16/118: Hepatitis C virus; GB virus C [GBV-C]
- A61K 39/42: viral
- A61P 31/14: for RNA viruses
- G01N 33/5767: {non-A, non-B hepatitis}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided are isolated monoclonal antibodies or any antigen-binding fragment thereof which bind to hepatitis C virus E2 protein (HCV E2). In particular the presently claimed subject matter concerns neutralizing anti HCV E2 antibodies, and their use for treating HCV infection. Furthermore, the presently claimed subject matter concerns methods for preparing neutralizing anti HCV scFv antibodies associated with HCV clearance.

## Claims

### Claim 1

An isolated monoclonal antibody or any antigen-binding fragment thereof which binds to hepatitis C virus E2 protein (HCV E2), wherein said antibody is selected from a group consisting of:
a. a monoclonal antibody comprising a heavy chain complementarity determining region (CDRH) 1 denoted by SEQ ID NO. 158, CDRH2 denoted by SEQ ID NO. 159, CDRH3 denoted by SEQ ID NO. 160, and the light chain complementarity determining region (CDRL) 1 denoted by SEQ ID NO. 163, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 165, or a variant thereof;
b. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 168, CDRH2 denoted by SEQ ID NO. 169, CDRH3 denoted by SEQ ID NO. 170, and a CDRL1 denoted by SEQ ID NO. 173, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 175, or a variant thereof;
c. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 108, CDRH2 denoted by SEQ ID NO. 109, CDRH3 denoted by SEQ ID NO. 110, and a CDRL1 denoted by SEQ ID NO. 113, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 115, or a variant thereof;
d. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 78, CDRH2 denoted by SEQ ID NO. 79, CDRH3 denoted by SEQ ID NO. 80, and a CDRL1 denoted by SEQ ID NO. 83, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 85, or a variant thereof;
e. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 59, CDRH2 denoted by SEQ ID NO. 60, CDRH3 denoted by SEQ ID NO. 61, and a CDRL1 denoted by SEQ ID NO. 64, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 66, or a variant thereof;
f. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 69, CDRH2 denoted by SEQ ID NO. 70, CDRH3 denoted by SEQ ID NO. 182, and a CDRL1 denoted by SEQ ID NO. 73, a CDRL2 denoted by SEQ ID NO. 74, and a CDRL3 denoted by SEQ ID NO. 75, or a variant thereof;
g. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 88, CDRH2 denoted by SEQ ID NO. 89, CDRH3 denoted by SEQ ID NO. 90, and a CDRL1 denoted by SEQ ID NO. 93, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 95, or a variant thereof;
h. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 98, CDRH2 denoted by SEQ ID NO. 99, CDRH3 denoted by SEQ ID NO. 100, and a CDRL1 denoted by SEQ ID NO. 103, a CDRL2 denoted by SEQ ID NO. 104, and a CDRL3 denoted by SEQ ID NO. 105, or a variant thereof;
i. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 118, CDRH2 denoted by SEQ ID NO. 119, CDRH3 denoted by SEQ ID NO. 120, and a CDRL1 denoted by SEQ ID NO. 123, a CDRL2 denoted by SEQ ID NO. 124, and a CDRL3 denoted by SEQ ID NO. 125, or a variant thereof;
j. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 128, CDRH2 denoted by SEQ ID NO. 129, CDRH3 denoted by SEQ ID NO. 130, and a CDRL1 denoted by SEQ ID NO. 133, a CDRL2 denoted by SEQ ID NO. 134, and a CDRL3 denoted by SEQ ID NO. 135, or a variant thereof;
k. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 138, CDRH2 denoted by SEQ ID NO. 139, CDRH3 denoted by SEQ ID NO. 140, and a CDRL1 denoted by SEQ ID NO. 143, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 145, or a variant thereof; and
l. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 148, CDRH2 denoted by SEQ ID NO. 149, CDRH3 denoted by SEQ ID NO. 150, and a CDRL1 denoted by SEQ ID NO. 153, a CDRL2 denoted by SEQ ID NO. 104, and a CDRL3 denoted by SEQ ID NO. 155, or a variant thereof.

### Claim 2

An isolated monoclonal antibody or any antigen-binding fragment thereof which binds to HCV E2, wherein said antibody comprises a heavy chain variable region and a light chain variable region, wherein said heavy chain variable region is encoded by a nucleic acid sequence which is at least 70% identical to the nucleic acid sequence denoted by SEQ ID NO. 156, SEQ ID NO. 166, SEQ ID NO. 106, SEQ ID NO. 76, SEQ ID NO. 57, SEQ ID NO. 67, SEQ ID NO. 86, SEQ ID NO. 96, SEQ ID NO. 116, SEQ ID NO. 126, SEQ ID NO. 136, SEQ ID NO. 146, and wherein said light chain variable region is encoded by a nucleic acid sequence which is at least 70% identical to SEQ ID NO. 161, SEQ ID NO. 171, SEQ ID NO. 111, SEQ ID NO. 81, SEQ ID NO. 62, SEQ ID NO. 71, SEQ ID NO. 91, SEQ ID NO. 101, SEQ ID NO. 121, SEQ ID NO. 131, SEQ ID NO. 141, SEQ ID NO. 151.

### Claim 3 (depends on 1, 2)

The isolated monoclonal antibody according to claim 1 or 2, wherein said antibody comprises a heavy chain variable region comprising the amino acid sequence denoted by SEQ ID NO. 157, SEQ ID NO. 167, SEQ ID NO. 107, SEQ ID NO. 77, SEQ ID NO. 58, SEQ ID NO. 68, SEQ ID NO. 87, SEQ ID NO. 97, SEQ ID NO. 117, SEQ ID NO. 127, SEQ ID NO. 137, SEQ ID NO. 147, or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by SEQ ID NO. 162, SEQ ID NO. 172, SEQ ID NO. 112, SEQ ID NO. 82, SEQ ID NO. 63, SEQ ID NO. 72, SEQ ID NO. 92, SEQ ID NO. 102, SEQ ID NO. 122, SEQ ID NO. 132, SEQ ID NO. 142, SEQ ID NO. 152, or a variant thereof.

### Claim 4 (depends on 1, 2)

The isolated monoclonal antibody according to claim 1 or 2, wherein said antibody is selected from a group consisting of:
a. a monoclonal antibody comprising a heavy chain variable region comprising the amino acid sequence denoted by SEQ ID NO. 157 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by SEQ ID NO. 162 or a variant thereof; and
b. a monoclonal antibody comprising a heavy chain variable region comprising the amino acid sequence denoted by SEQ ID NO. 167 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by SEQ ID NO. 172 or a variant thereof.

### Claim 5 (depends on 1)

The isolated monoclonal antibody according to claim 1, wherein said antibody is a human antibody.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

An isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or any antigen-binding fragment thereof according to claim 1.

### Claim 8 (depends on 7)

An expression vector or a host cell comprising the isolated nucleic acid molecule according to claim 7.

### Claim at position 9

-10. (canceled)

### Claim 11 (depends on 1)

A pharmaceutical composition comprising as an active ingredient the isolated monoclonal antibody or any antigen-binding fragment thereof according to claim 1 and a pharmaceutically acceptable carrier, excipient or diluent.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11, wherein said composition further comprises an additional anti-HCV agent.

### Claim 13 (depends on 1)

A method of prophylaxis, treatment or amelioration of HCV infection comprising administering to a subject in need thereof a therapeutically effective amount of the isolated monoclonal antibody or any antigen-binding fragment thereof according to claim 1.

### Claim 14 (depends on 13)

The method according to claim 13, wherein said method further comprises administering to a subject in need thereof an additional anti-HCV agent.

### Claim 15 (depends on 14)

The method according to claim 14, wherein said antibody is administered at a therapeutically effective amount of 10-1000 μg/kg.

### Claim 16 (depends on 1)

A method of detecting HCV in a biological sample obtained from a subject, said method comprising:
(a) contacting said biological sample with the isolated monoclonal antibody or any antigen-binding fragment thereof according to claim 1, wherein said monoclonal antibody is labeled with a detectable marker; and
(b) detecting said isolated monoclonal antibody or any antigen-binding fragment thereof;
wherein the presence of said isolated monoclonal antibody or any antigen-binding fragment thereof indicates the presence of HCV in said biological sample.

### Claim 17 (depends on 1)

A kit for detecting HCV comprising:
(a) at least one labeled isolated monoclonal antibody or any antigen-binding fragment thereof according to claim 1;
(b) means for detection of said labeled isolated monoclonal antibody; and optionally
(c) instructions for use of said kit.

### Claim 18

A method of preparing neutralizing anti HCV scFv antibodies associated with HCV clearance, comprising the steps of:
a. constructing a phage display scFv antibody library from peripheral blood mononuclear cells (PBMC) obtained from Spontaneous clearer (SC) individuals;
b. identifying at least one HCV E2 binder;
c. comparing the sequence of the at least one HCV E2 binder with the sequences in stratifying clusters from a general repertoire that are associated with HCV clearance;
d. selecting an scFv sequence with high similarity to a sequence in a stratifying cluster from said general repertoire that is associated with HCV clearance.

### Claim 19 (depends on 18)

The method of claim 18 wherein the scFv library construction comprises the steps of:
a. amplification of the Heavy chain variable region (VH) and Light chain variable region (VL) genes separately;
b. combinatorial assembly of the VH and VL genes; and
c. cloning into a phagemid vector.

### Claim 20 (depends on 18)

The method of claim 18 wherein the identification of the at least one HCV E2 binder comprises screening for phages that bind to rE2.

### Claim 21 (depends on 18)

The method of claim 18 wherein the stratifying clusters are selected from the clusters denoted in Tables 3 and 4.

### Claim 22 (depends on 18)

The method of claim 18 further comprising the step of converting the scFv to full-length antibodies.

### Claim 23 (depends on 22)

The method of claim 22 wherein the full-length antibodies comprise a light chain of the selected scFv antibody and a heavy chain of one of the sequences that show high similarity to the scFv heavy chain from the general repertoire.

### Claim 24

(canceled)
